Growth Hormone

Normally, rising blood volume triggers a compensatory renal mechanism that increases sodium excretion (pressure natriuresis). Researchers found that growth hormone blunts this safety-valve response, compounding the sodium and fluid retention. This dual mechanism — increased reabsorption plus suppressed compensation — explains why the retention can be pronounced.

The speaker explains that growth hormone activates the renin-angiotensin-aldosterone system (RAAS), which is the hormonal pathway governing renal sodium handling. When RAAS is activated by GH, the kidneys reabsorb sodium back into the bloodstream rather than excreting it. This is presented as a research-supported mechanism rather than purely anecdotal observation.

The speaker recommends replacing AOD-9604 with regular exogenous growth hormone, arguing it provides equal or greater benefit for body composition and lipolysis. No specific dosage protocol is provided in this excerpt. The recommendation is framed as a superior alternative given AOD-9604's failed clinical trial record.

The speaker offers a reassurance-oriented safety framing, characterizing water retention from GH peptides as a completely normal and expected side effect rather than a dangerous one. He suggests that understanding the underlying mechanism reduces anxiety about the symptom. The implicit safety guidance is that the side effect is acceptable as long as the user can tolerate the physical discomfort.

The speaker states that in most cases, water retention from growth hormone peptides resolves on its own within approximately three to four weeks as the body's counter-regulatory systems adjust to the new hormonal baseline. This is described as the simplest and most reliable solution. The speaker frames this as a normal, tolerable side effect rather than a safety concern.

The speaker recommends increasing dietary potassium intake to help offset GH-induced sodium retention. The mechanism cited is that potassium activates a separate renal pathway that promotes sodium excretion, independent of the RAAS pathway activated by GH. No specific potassium dosage or food sources are mentioned.

The speaker recommends starting at a lower dose of growth hormone peptides and titrating upward slowly as a primary mitigation strategy for water retention. The rationale is that the fluid retention is dose-dependent, and the kidneys require time to adapt to the hormonal changes induced by GH. No specific starting dose or titration schedule is provided.

Growth hormone and growth hormone peptides cause water retention by signaling the kidneys to reabsorb sodium. Because sodium retention drives fluid retention, this manifests as visible edema in the face, hands, and ankles. The speaker presents this as the core mechanistic explanation for a commonly reported side effect.